Concise review: Bone marrow autotransplants for liver disease?

Authors

  • Iman Saramipoor Behbahan,

    Corresponding author
    1. Department of Biological Chemistry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    • Correspondence: Iman Saramipoor Behbahan, M.D., Department of Biological Chemistry, David Geffen School of Medicine, University of California Los Angeles, BSRB 357-08, 615 Charles E. Young Drive E., Los Angeles, California 90095, USA. Telephone: +1-310-794-5194; Fax: +1-310-206-1929; e-mail: isaramipoor@gmail.com

    Search for more papers by this author
  • Armand Keating,

    1. Division of Hematology, University of Toronto, Cell Therapy Program, Princess Margaret Hospital, Toronto, Canada
    Search for more papers by this author
  • Robert Peter Gale

    1. Section of Haematology, Division of Medicine, Department of Medicine, Imperial College London, London, United Kingdom
    Search for more papers by this author

  • Author contributions: I.S.B., A.K., and R.P.G.: conception, design, research, writing and financial support; final manuscript was approved by all authors. Manuscript was supported in part by Celgene corporation.

Abstract

There are increasing reports of using bone marrow-derived stem cells to treat advanced liver disease. We consider several critical issues that underlie this approach. For example, are there multipotent stem cell populations in human adult bone marrow? Can they develop into liver cells or supporting cell types? What are stromal stem/progenitor cells, and can they promote tissue repair without replacing hepatocytes? Does reversal of end-stage liver disease require new hepatocytes, a new liver microenvironment, both, neither or something else? Although many of these questions are unanswered, we consider the conceptual and experimental bases underlying these issues and critically analyze results of clinical trials of stem cell therapy of end-stage liver disease. Stem Cells 2013;31:2313–2329

Ancillary